All Publications

Export 160 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Rapid Increase in the Frequency of Wild Type HIV-1 Drug Resistance Reports among ART-experienced Patients: UK Dolling D, Nelson M, Schwenk A, Churchill D, Pillay D, Dunn D and UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study. 20th Conference on Retroviruses and Opportunistic Infections, 2013, (2013)
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. Phillips A, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J et al. AIDS, 2007 Aug 20, Volume 21, Issue 13, p.1717-21, (2007)
Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study O'Connor J, Smith C, Lampe F, Johnson M, Sabin C and Phillips A. International Congress of Drug Therapy in HIV Infection, 2014, Volume J Int AIDS Soc 2014, 17(Suppl 3):19527, (2014)
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. Smith C, Phillips A, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G et al. J Infect Dis, 2005 Oct 15, Volume 192, Issue 8, p.1387-97, (2005)
REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. Howarth A, Apea V, Michie S, Morris S, Sachikonye M, Mercer C, Evans A, Delpech V, Sabin C and Burns F. Health Services and Delivery Research, Volume 5, Issue 13, (2017)
Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients. Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, Monforte A, Mary-Krause M, Roca B, Miro J et al. HIV Med, 2017 Jan, Volume 18, Issue 1, p.33-44, (2017)
Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women. Huntington S, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. BMC Infect Dis, 2014 Mar 04, Volume 14, p.127, (2014)
Response to combination antiretroviral therapy: variation by age. Sabin C, Smith C, Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A et al. AIDS, 2008 Jul 31, Volume 22, Issue 12, p.1463-73, (2008)
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C, Bansi L, Gompels M et al. HIV Med, 2011 May, Volume 12, Issue 5, p.289-98, (2011)
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). Mocroft A, Lundgren J, Sabin M, Monforte A, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S et al. PLoS Med, 2013, Volume 10, Issue 9, p.e1001510, (2013)
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Kesselring A, Wit F, Sabin C, Lundgren J, M Gill J, Gatell J, Rauch A, Montaner J, de Wolf F, Reiss P et al. AIDS, 2009 Aug 24, Volume 23, Issue 13, p.1689-99, (2009)
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte A, Rakhmanova A, Phillips A et al. Antivir Ther, 2007, Volume 12, Issue 3, p.325-33, (2007)
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Phillips A, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J et al. Lancet, 2007 Dec 08, Volume 370, Issue 9603, p.1923-8, (2007)
The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. Huntington S, Thorne C, Newell M, Anderson J, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2015 Nov, Volume 29, Issue 17, p.2269-78, (2015)
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D and Phillips A. Antivir Ther, 2013, Volume 18, Issue 2, p.213-9, (2013)
Spectrum of HIV-associated kidney disease in the era of combination antiretroviral therapy. Booth J, Hamzah L, Jose S, McAdoo S, Kumar E, Horsfield C, O'Donnell P, Jones R, Sabin C and Post F. Conference on retroviruses and opportunistic infections (CROI) 2014, Volume Top Antivir Med 2014;22(e-1):410, p.Abstract 793 Poster, (2014)
A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell A, Cooper C, Hill T et al. HIV Med, 2017 Apr 24, (2017)
A time-updated continuum of care in a UK cohort Howarth A, Hill T, Burns F, Sabin C, Jose S and Delpech V. 23nd Annual Conference of the British HIV Association (BHIVA), Volume HIV Medicine, 18 (Suppl. S1), 3–13, p.Oral O15, (2017)
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. Sabin C, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle M, Johnson M, Fisher M, Scullard G et al. BMJ, 2005 Mar 26, Volume 330, Issue 7493, p.695, (2005)
Treatment for hepatitis C infection in the UK Collaborative HIV Cohort (UK CHIC) study Rodger A, Thornton A, Sabin C, Jose S, Dunn D, Gilson R, Bhagani S, Chadwick D, Fisher M, Main J et al. 21st Annual Conference of the British HIV Association (BHIVA), 2015, Volume HIV Medicine, 2015; 16 (Suppl. 2), 12–77, p.Oral 20, (2015)
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Lee K, Dunn D, Gilson R, Porter K, Bansi L, Hill T, Phillips A, Sabin C, Schwenk A, Leen C et al. AIDS, 2008 Oct 01, Volume 22, Issue 15, p.1943-50, (2008)
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. Huntington S, Bansi L, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2011 Aug 24, Volume 25, Issue 13, p.1647-55, (2011)
Treatment switches following periods of low-level viraemia Jose S, Smit E, Martin F, Dunn D, Mackie N, Churchill D and Sabin C. Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH), 2014, Volume HIV Medicine 2014; 15 (Suppl. 3), 17-159, p.Poster 156, (2014)
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, De Luca A et al. Lancet Infect Dis, 2012 Feb, Volume 12, Issue 2, p.119-27, (2012)
Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P, Gilson R, Johnson M et al. HIV Med, 2010 Aug, Volume 11, Issue 7, p.432-8, (2010)